RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Study ID
- NCT00307593
- Status
- Completed
Conditions
- Churg-Strauss Syndrome
- Microscopic Polyangiitis
- Wegener's Granulomatosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Infliximab — DRUGInfliximab
- Rituximab — DRUGRituximab
Study Details
The purpose of this study is to compare a 2 immunosuppressant regimen for the treatment of relapsing or refractory necrotizing antineutrophil cytoplasmic antibody (ANCA) associated vasculitides.
Key Dates
- Start date
- May 31, 2004
- Status verified
- Mar 2007
- Completion
- Jun 30, 2007
Study Design
- Enrollment
- 20 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- FACTORIAL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: 1Rituximab
- Active Comparator: 2Infliximab
Primary Outcome Measure
Partial or complete remission of the vasculitides [ Time Frame: one year ]
Related Studies
- Longitudinal Study for Eosinophilic Granulomatosis With PolyangiitisRecruiting · University of Pennsylvania · San Diego, California
- One-Time DNA Study for VasculitisRecruiting · University of Pennsylvania · Los Angeles, California
- Vasculitis Pregnancy RegistryRecruiting · University of Pennsylvania · Tampa, Florida
- VCRC Tissue RepositoryRecruiting · University of Pennsylvania · Boston, Massachusetts